1414376-85-4

Basic information

• Product Name: VUF11418
• Synonyms: VUF11418
• CAS NO: 1414376-85-4
• Molecular Formula: C₂₅H₃₁IN*I
• Molecular Weight: 599.32928
• Mol File: 1414376-85-4.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: VUF11418(CAS DataBase Reference)
• NIST Chemistry Reference: VUF11418(1414376-85-4)
• EPA Substance Registry System: VUF11418(1414376-85-4)

Safety Data

• Hazardous Substances Data: 1414376-85-4(Hazardous Substances Data)

Usage

General Description

VUF11418 is a chemical compound that acts as a potent and selective antagonist for the metabotropic glutamate receptor subtype 5 (mGlu5). VUF11418 has been found to exhibit high affinity for mGlu5 receptors, with a Ki value of 58 nM. It has been used in research to study the role of mGlu5 receptors in various neurological and psychiatric disorders, including schizophrenia, anxiety, and addiction. VUF11418 has shown promise as a potential therapeutic agent for these conditions, and its unique pharmacological profile makes it a valuable tool for further investigation of mGlu5 receptor function.

Upstream product

• 312612-56-9 2'-iodo-[1,1'-biphenyl]-4-carbaldehyde 
• 615-42-9 1,2-Diiodobenzene 
• 87199-17-5 4-formylphenylboronic acid, 
• 1413777-35-1 1-((1R,5S)-6,6-dimethylbicyclo[3.1.1]hept-2-en-2-yl)-N-((2'-iodobiphenyl-4-yl)methyl)-N-methylmethanamine 
• 74-88-4 methyl iodide 

Relevant articles and documents

Chemical subtleties in small-molecule modulation of peptide receptor function: The case of CXCR3 biaryl-type ligands

The G protein-coupled chemokine receptor CXCR3 plays a role in numerous inflammatory events. The endogenous ligands for the chemokine receptors are peptides, but in this study we disclose small-molecule ligands that are able to activate CXCR3. A class of biaryl-type compounds that is assembled by convenient synthetic routes is described as a new class of CXCR3 agonists. Intriguingly, structure-activity relationship and structure-function relationship studies reveal that subtle chemical modifications on the outer aryl ring (e.g., either the size or position of a halogen atom) result in a full spectrum of agonist efficacies on CXCR3. Quantum mechanics calculations and nuclear Overhauser effect spectroscopy NMR studies suggest that the biaryl dihedral angle and the electronic nature of ortho-substituents play an important role in determining agonist efficacies. Compounds 38 (VUF11222) and 39 (VUF11418) are the first reported nonpeptidomimetic agonists on CXCR3, rendering them highly useful chemical tools for detailed assessment of CXCR3 activation as well as for studying downstream CXCR3 signaling.